Boston Scientific, Medinol Coronary Stent IDE Approvals Precede Legal Duel
This article was originally published in The Gray Sheet
Executive Summary
Medinol's April 2001 lawsuit alleging Boston Scientific's development of the Express stent constitutes a breach of contract will likely be heard in New York federal court by late summer
You may also be interested in...
Medinol Was Boston Scientific’s First And Final Pipeline Partner, CFO Vows
Boston Scientific is extracting a painful lesson from its failed business relationship with former stent partner Medinol: never delegate manufacturing and R&D authority to another firm
Medinol Was Boston Scientific’s First And Final Pipeline Partner, CFO Vows
Boston Scientific is extracting a painful lesson from its failed business relationship with former stent partner Medinol: never delegate manufacturing and R&D authority to another firm
Boston Scientific Paclitaxel Stent Restenosis Rate Is Zero At Six Months
Results of a 61-patient, three-center German study of Boston Scientific's paclitaxel-coated NIRx coronary stent appear to match the high standards established in recently released drug-coated stent studies sponsored by Johnson & Johnson/Cordis and Cook.